Industry
Biotechnology
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Loading...
Open
3.08
Mkt cap
113M
Volume
414K
High
3.09
P/E Ratio
-1.80
52-wk high
5.00
Low
2.87
Div yield
N/A
52-wk low
1.68
Portfolio Pulse from
November 26, 2024 | 12:15 pm
Portfolio Pulse from
November 13, 2024 | 12:15 pm
Portfolio Pulse from Benzinga Newsdesk
September 30, 2024 | 11:07 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 11:25 am
Portfolio Pulse from Benzinga Newsdesk
June 28, 2024 | 4:46 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 11:49 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:11 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:09 am
Portfolio Pulse from Benzinga Newsdesk
April 19, 2024 | 8:43 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.